This is the fifth article in this series. Drs. Trembath and Harrison describe genetic mutations responsible for Primary Pulmonary Hypertension and their relation to other forms of genetic and acquired pulmonary vascular disease.
The pathogenesis of primary pulmonary hypertension (PPH) remains poorly understood. Molecular genetic studies have identified that mutations within the gene BMPR2 on the long arm of chromosome 2 underlie familial PPH. This review explores the significance of the PPH gene identification and examines additional genetic determinants, emphasizing the immediate implications for assessment and management of patients and their relatives. 
PULMONARY ARTERIAL HYPERTENSION
Pulmonary arterial hypertension (PAH) describes a spectrum of diseases defined by a sustained increase in pulmonary artery pressure (mean Ͼ25 mm Hg at rest and Ͼ30 mm Hg during exercise). PAH is typically associated with endothelial and vascular smooth muscle cell proliferation within small pulmonary arteries ( Fig. 1) (1). Raised pulmonary artery pressures lead to progressive right heart hypertrophy and eventual failure.
The diagnostic classification of PAH has recently been revised to distinguish between primary pulmonary hypertension and PAH occurring in association with other conditions including connective tissue diseases, HIV infection, portal hypertension, or use of appetite suppressants ( Table 1) . The classification also distinguishes between conditions for which the underlying cause of elevated pulmonary artery pressure is known and for which specific therapeutic approaches exist, such as chronic thromboembolic disease, chronic hypoxic lung disease and left sided cardiac disease.
PRIMARY PULMONARY HYPERTENSION
Primary pulmonary hypertension (PPH) is a devastating disease, the pathogenesis of which remains poorly defined. gender ratios are observed for cases with and without a family history of disease), suggesting that hormonal factors may be important in disease development, or that genetic (X-linked) factors may influence predisposition to disease (2, 9) . PPH typically occurs as a sporadic disorder, yet figures from the National Institutes of Health registry demonstrate that at least 6% of PPH patients report a family history of the disease (2) . Importantly, the natural history of PPH appears similar in both familial and sporadic forms of the disease. In families, PPH segregates as an autosomal dominant trait, the disease gene acting with markedly reduced penetrance (9) such that a PPH gene carrier may have no greater than a 10% to 20% chance of developing the clinical disorder (10) . The age of onset of clinical disease in PPH gene carriers is highly variable, both within and between PPH families. Anticipation, a phenomenon by which successive generations are affected at an earlier age, is observed in some families (11) .
Taken together these observations indicate that a genetic susceptibility is not sufficient to cause disease, but that diverse environmental exposures may trigger disease in genetically susceptible individuals.
SEARCH FOR A PPH GENE
In 1997, two independent groups searching for a PPH gene established linkage to the long arm of chromosome 2 at 2q 31-33 (12, 13) . Analysis of over 40 independently ascertained families revealed that all affected subjects in these families shared a similar chromosomal region (14, 15) . Analysis of crossover (recombination) events within families enabled further reduction of the critical interval for the PPH gene (16, 17) , and sequence analysis of potential candidate genes in this region identified heterozygous mutations within the gene bone morphogenetic protein receptor-2 -BMPR2 (14, 18).
BMPR-II AND THE TGF-␤ SUPERFAMILY
The BMPR2 product (BMPR-II) is a receptor in the multifunctional transforming growth factor-beta (TGF-␤) signaling pathway. The ligands for this receptor -bone morphogenetic proteins (BMPs) -are peptides required for growth and differentiation of bone and cartilage. Both TGF-␤ and BMPs are necessary for differentiation, proliferation and apoptosis of many cell types and have critical roles in embryogenesis (19, 20) . All members of the TGF-␤ superfamily signal by binding to types I and II cell surface receptors and activating serine/ threonine kinases through the formation of heteromeric complexes (21) (Fig. 2) .
Defects in the TGF-␤ signaling pathway have been implicated in numerous disease states. Mutations in the genes for components of the TGF-␤ signaling pathway contribute to the pathogenesis of cancer and underlie the inherited vascular disorder hereditary hemorrhagic telangiectasia (HHT), while acquired changes in TGF-␤ function have been observed in a wide range of disorders including fibrotic disease of the lung and atherosclerosis (22, 23) .
BMPR2 MUTATIONS IN FAMILIAL AND SPORADIC PPH
Over 40 unique heterozygous BMPR2 mutations have been identified in patients with a known family history of PPH, accounting for nearly 55% (40 of 73) of families studied (14, 18) (also see www.pphgenes.net for an updated list of identified PPH associated mutations). It is important to note that these are germline mutations, represented in all cell types. Mutations are widely dispersed throughout the distinct functional domains of the gene, and appear to be unique or "private" to each family studied (Fig. 3) . This variety of mutations will complicate attempts to design simple diagnostic genetic tests for the disease.
A number of explanations may account for the failure to detect mutations in a proportion of familial PPH. Deleterious mutations may occur in gene regions that have not routinely been sequenced, such as regulatory or intronic sequences. Large-scale gene rearrangements will also have been missed by direct sequencing methods. Additionally, it remains possible that other genes, yet to be identified, contribute to the genetic basis of PPH.
In a study of fifty PPH patients with no family history, germline mutations in BMPR2 were identified in almost one third (24) with the range of mutations paralleling those seen in recognized familial cases. Some of these mutations were inherited from apparently healthy parents, others arose spontaneously (de novo). BMPR2 mediated genetic susceptibility to PPH is an important contributor to the etiology of this devastating disorder.
FROM GENE TO DISEASE
BMPR2 mutations described are predicted to interrupt the signaling pathways mediated by BMPR-II protein, resulting in a predisposition to proliferation rather than apoptosis of cells within the small pulmonary arteries. In support of this hypothesis, BMPs appear to suppress proliferation of pulmonary artery smooth muscle cells from healthy individuals and patients with secondary forms of pulmonary hypertension, yet fail to suppress proliferation in patients with primary pulmonary hypertension (25) . Expression of BMPR-II in pulmonary vascular endothelium appears markedly reduced in PPH patients, particularly in those who have mutations in BMPR2 (26) . Such a reduction in cell surface receptors may be sufficient to disrupt normal signaling pathways. The precise molecular mechanisms by which BMPR2 mutations predispose to the vascular changes that characterize PPH, are the subject of further intense study.
However, a mutation within BMPR2 is clearly not sufficient to cause onset of disease. Anorexigens are known to have caused epidemics of PAH in the general population, although the vast majority of individuals taking such drugs do not develop disease. When a group of 33 patients with anorexigenassociated PAH was studied, BMPR2 mutations were found in three patients with no family history of pulmonary hypertension (27) , with an additional mutation identified in two sisters with familial PPH. These data suggest that BMPR2 mutations may not be the major genetic susceptibility contributing to disease associated with anorexigens.
ADDITIONAL GENETIC DETERMINANTS
Pulmonary artery smooth muscle cells from PPH patients grow faster than those from controls when stimulated by serotonin or serum, a finding that correlates with increased expression of the serotonin transporter (28) . Genetic analysis of variation in the promoter region of the serotonin transporter gene (5HTT) is associated with overexpression of 5HTT and may also contribute to a genetic susceptibility to PPH (28) . Whether 5HTT mediated susceptibility acts independent of BMPR2 gene variation has yet to be examined.
The acquisition of somatic mutations may also contribute to the pathogenesis of PPH. Analysis of plexiform lesions (intravascular lesions of disorganized endothelial cell proliferation typical of PPH) from the lungs of PPH patients showed that endothelial cell proliferation was predominantly monoclonal, whereas plexiform lesions from patients with secondary PAH were entirely polyclonal (29) . Proliferating endothelial cells in plexiform lesions from PPH patients show microsatellite instability. Mutations within microsatellites are not present in germline DNA, and are associated with decreased protein expression of the TGF-␤ receptor II within the plexiform lesion (30) . These observations indicate that somatic genetic alterations similar to those involved in neoplasia, may contribute to pulmonary arterial hypertension.
HEREDITARY HEMORRHAGIC TELANGIECTASIA AND PULMONARY HYPERTENSION
Hereditary hemorrhagic telangiectasia (HHT) is a vascular dysplasia characterized by abnormal vessel wall development, with the formation of mucocutaneous telangiectases and arteriovenous malformations within the pulmonary, hepatic or cerebral circulations. Mutations in two genes encoding TGF-␤ receptors, the endoglin gene (ENG) on chromosome 9, and the activin-receptor-like kinase 1 gene (ALK1) on chromosome 12 (31, 32) , have been shown to underlie HHT. Patients with HHT may develop pulmonary hypertension that is clinically and pathologically indistinguishable from PPH (33, 34) .
Five kindreds and one individual were identified with a family history of HHT and cases of pulmonary hypertension (35) . Novel defects of ALK1 were demonstrated in each family suggesting that these mutations may contribute to the development of PH as well as HHT. Molecular mechanisms linking the two disease processes remain to be elucidated and ALK1 defects have not been found in families with PPH alone. However, the TGF-␤ cell-signaling pathway is known to have diverse effects in control of cell types within the vasculature. For example, overexpression of TGF-␤ simultaneously promotes both intimal growth and apoptosis of vascular endothelium (36) . Elucidating such cell specific interactions will be crucial to gaining a detailed molecular understanding of the pathogenesis of PPH.
CLINICAL SCREENING AND GENETIC TESTING
Recognition of the inherited nature of a significant proportion of PPH may understandably cause concern for individuals affected by PPH. Clinical screening has been recommended for first-degree relatives of PPH patients and may include a chest x-ray, ECG, and echocardiogram. Identifying earlier stages in the progression to sustained pulmonary hypertension will be critical to determine whether treatment started at the earliest opportunity can improve outcome.
Genetic analysis of BMPR2 may now be performed in PPH patients, and if mutations are identified, presymptomatic genetic testing offered to their relatives. This approach may have advantages in streaming clinical screening, with the prospect of potential benefit from early intervention together with avoidance of factors known to precipitate or exacerbate PPH. These include pregnancy, hypoxic environments, and anorexic drugs. Children should not be excluded from presymptomatic genetic testing as PPH may affect this age group. Clinical screening for features of PPH should therefore be considered from early years onwards. However, further research is necessary to improve understanding of the predictive value of mutation detection and a clinical screening program. For example, it is currently unclear whether different mutations predict different disease penetrance, susceptibility to particular environmental factors or response to treatment. Recent studies report that obligate gene carriers in families with PPH have elevated peak pulmonary artery pressures, when assessed by stress Doppler echocardiography during supine exercise (37) . It is also important to emphasize that failure to identify a BMPR2 mutation in an individual with PPH does not exclude a familial form of disease. It is therefore vital that genetic analysis only takes place after full genetic counseling to ensure that families understand the current limitations of genetic testing in PPH.
